Stay updated with breaking news from Study Protocols. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A novel allergen and immunotherapy adherence and persistence checklist was developed to allow for more insight into adherence and to open this information to prescribing clinicians.
The past few years have highlighted the importance of scientific research and communication as researchers from multiple disciplines came together to fight SARS-CoV-2. However, trust in research has also suffered as a number of high profile retractions of Covid-19 research have featured in the mainstream media. This, against a backdrop of increasing retractions in scientific publishing, confirms the central role of structures to uphold research integrity to safeguard trust in science. In recognition of this, the theme for this year’s Peer Review Week is “Research Integrity: Creatin...
12.08.2022 - Paltusotine’s Phase 3 PATHFNDR Program in Acromegaly and Phase 2 Program in Carcinoid Syndrome Remain on Track for Top-Line Data in 2023 CRN04894 Phase 1 Data Demonstrated Pharmacologic Proof-of-Concept for Further Development in Both Cushing’s ...
An update on Lab and Study Protocols at PLOS ONE Emily Chenette, Editor-in-Chief, PLOS ONE PLOS empowers researchers to transform science by offering more options for credit, transparency and choice. The launch of Lab Protocols and Study Protocols in PLOS ONE earlier this year supported this crucial goal by bringing reproducibility and transparency to research, and enabling those who contributed to study design to receive credit for their contributions. Today, we’re delighted to share the news that two Study Protocols have now been published in PLOS ONE. The first, by Satoru Joshita a...
A new Editor-in-Chief for PLOS ONE PLOS ONE community, What a joy it is to write this letter – to have the opportunity to reflect on the strengths of PLOS ONE and consider how we can best meet your needs in the years ahead. I’m writing to you to share what you can expect from me as Editor-in-Chief of PLOS ONE, and to call for your feedback and your perspective on what we’ve gotten right, and where we can improve. I am a molecular biologist by training. I received my PhD in Genetics and Molecular Biology from the University of North Carolina at Chapel Hill in 2004, and studied gene exp...